Photo by nci from unsplash
We thank Favalli et al for their interest in our study reporting the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) in a case series of… Click to show full abstract
We thank Favalli et al for their interest in our study reporting the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) in a case series of 17 patients with systemic lupus erythematosus (SLE) under long-term treatment with hydroxychloroquine (HCQ).1 2 As mentioned in our study, we did not aim at reporting the incidence rate and the severity of COVID-19 in SLE, because our cohort most likely over-represents the most symptomatic and severe cases, as a result of a bias in the selection procedure of the patients used by the physicians. Favalli et al , by studying the nasopharyngeal carriage of SARS-CoV-2, confirm the low prevalence of COVID-19 in their cohort …
Journal Title: Annals of the Rheumatic Diseases
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!